Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» RNAi
RNAi
Arrowhead axes assets, but spares staff, to save $100M a year in refocus on core areas
Fierce Biotech
Wed, 02/7/24 - 11:21 am
Arrowhead Pharmaceuticals
RNAi
Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance
Fierce Biotech
Mon, 01/8/24 - 11:33 am
Novartis
Calypso
M&A
RNAi
JPMHC 2024
With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam
Fierce Pharma
Mon, 10/2/23 - 06:36 pm
Novo Nordisk
Rivfloza
FDA
primary hyperoxaluria type 1
RNAi
Alnylam
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
Mon, 07/24/23 - 11:29 am
Roche
Alnylam
RNAi
hypertension
zilebesiran
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
Tue, 07/18/23 - 11:55 am
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
4DMT provides clinical programme updates for its wet AMD gene therapy
Clinical Trials Arena
Tue, 07/18/23 - 11:40 am
4D Molecular Therapeutics
wet age-related macular degeneration
RNAi
4D-150
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
Wed, 02/15/23 - 06:08 pm
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Fri, 10/28/22 - 10:25 am
Alnylam
RNAi
vutrisiran
Stargardt disease
Inflation Reduction Act
drug pricing
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Businesswire
Mon, 08/29/22 - 10:26 am
Alnylam Pharmaceuticals
clinical trials
cemdisiran
Regeneron
IgAN
immunoglobultin A nephropathy
RNAi
Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'
Endpoints
Mon, 04/4/22 - 11:08 pm
Alnylam
RNAi
FDA
vutrisiran
Another biotech shuffles its C-suite as Silence CEO steps down
Endpoints
Tue, 02/22/22 - 10:54 am
Silence Therapeutics
Pharma CEOs
RNAi
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
Fierce Biotech
Mon, 11/22/21 - 10:19 pm
GSK
Arrowhead Pharmaceuticals
NASH
RNAi
Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna
Fierce Biotech
Thu, 11/18/21 - 10:54 am
Novo Nordisk
M&A
Dicerna Pharmaceuticals
RNAi
Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win
Endpoints
Thu, 08/5/21 - 11:24 pm
Dicerna
RNAi
Primary Hyperoxaluria
clinical trials
Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial
BioSpace
Mon, 08/2/21 - 11:06 am
Alnylam
RNAi
renal decline
clinical trials
lumasiran
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Endpoints
Fri, 07/2/21 - 11:04 am
Arrowhead Pharmaceuticals
RNAi
animal research
cystic fibrosis
Eli Lilly Collab Scores IND Approval for Dicerna's RNAi Cardiometabolic Drug
BioSpace
Thu, 05/27/21 - 11:09 am
Dicerna
Eli Lilly
LY3819469
clinical trials
RNAi
cardiometabolic diseases
Novartis’s big wager on RNAi approaches the finish line
EP Vantage
Wed, 11/25/20 - 10:27 am
Novartis
RNAi
COVID-19
Leqvio
cholesterol
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?
Motley Fool
Sun, 10/18/20 - 08:32 pm
Alnylam
Vir Biotechnology
RNAi
vaccines
COVID-19
Pages
1
2
3
4
5
6
next ›
last »